Genmab — August 2020
-
@Pensionisten - Det må være fredagsvitsen.
-
GRIFFIN trial published in Blood https://twitter.com/slentzsch/status/1296600541758476291?s=21
-
Comment from Dr. Suzanne Lentzsch „my new SOC“
-
God morgen.
-
God morgen
-
twitter: Jeffrey Cranmer
@jeff_cranmer
Pandemic could give a leg up to #MultipleSclerosis newcomer Kesimpta ofatumumab / At an annual WAC of $83K, #Kesimpta is more $$$ than a 300 mg dose of Ocrevus from
@genentech
($16K-_>$65K/yr; but Bulto noted that the auto-injector avoids the added costs of infusions. https://twitter.com/jeff_cranmer/status/1296595805030117376 -
Die US-Investmentbank Goldman Sachs hat Novartis
nach einer unerwartet frühen US-Zulassung für das Multiple-Sklerose-Medikament
Kesimpta (Ofatumumab) auf der "Conviction Buy List" mit einem Kursziel von 108
Franken belassen. Analyst Keyur Parekh sprach in einer am Freitag vorliegenden
Studie von einer klar positiven Nachricht für den Schweizer Pharmakonzern. Der
Jahresumsatz mit dem Medikament könnte bis 2024 bis auf 1,4 Milliarden US-Dollar steigen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind